The method triggers immune responses that inhibit melanoma, triple-negative breast cancer, lung carcinoma, and ovarian cancer ...

Mount Sinai scientists will continue studying PGV001 in larger groups of patients and testing how it works with other cancer treatments. Data from this phase 1 study have prompted three additional ...

Hello Health Rounds Readers! Today we feature a study that found seniors may be less vulnerable to bird flu than younger adults and children. We also report on studies that could lead to practice ...

The vaccine uses multiple peptides (amino acid ... one in urothelial cancer in combination with an ICI, and another in prostate cancer. Multiple researchers from the Icahn School of Medicine ...

Researchers at the Icahn School of Medicine at Mount Sinai, led by Nina Bhardwaj, MD, Ph.D., Ward-Coleman Chair in Cancer ...

“The commonest cancer we have that affects women and even kills them is cancer of the cervix. On average, we see four to five ...

Merck’s Keytruda is also being studied in numerous vaccine combination trials, including in prostate cancer, bladder cancer, colorectal and pancreatic cancer. One of the agents being studied in ...

In an interview with pharmaphorum, Goodfellow said the backing of CRUK was an endorsement of Scancell and its cancer vaccine platform. After years of failures (most notably prostate cancer vaccine ...

Androgen-deprivation therapy (ADT) plus vaccine: ADT has been shown to potentiate immune responses and mitigate immune tolerance to prostate cancer antigens. Chemotherapy plus vaccine: Certain ...

There are a few FDA-approved immunotherapy options for prostate cancer, including Sipuleucel-T, a vaccine comprised of individuals’ immune cells to boost their immune response. It’s approved ...